Bimekizumab for patients with moderate-to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study (supplemental materials)

Published: 8 June 2020| Version 1 | DOI: 10.17632/5ry2hmc2wm.1
Contributors:
Andrew Blauvelt,
Kim A. Papp,
Joseph F. Merola,
Alice B. Gottlieb,
Nancy Cross,
Cynthia Madden,
Maggie Wang,
Christopher Cioffi,
Christopher E.M. Griffiths

Description

Supplemental materials for the manuscript: 'Bimekizumab for patients with moderate- to-severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled phase 2b extension study.' Includes supplemental methods for the BE ABLE 2 phase 2b trial, patient demographics and baseline characteristics, incidence of serious treatment-emergent adverse events in the trail, patient disposition flowchart, PASI90 reponse rates over time in Week 12 PASI90 responder and non-responder subgroups, and PASI100 response rates over time in Week 12 PASI90 responders.

Files